156 research outputs found
Large N 2D Yang-Mills Theory and Topological String Theory
We describe a topological string theory which reproduces many aspects of the
1/N expansion of SU(N) Yang-Mills theory in two spacetime dimensions in the
zero coupling (A=0) limit. The string theory is a modified version of
topological gravity coupled to a topological sigma model with spacetime as
target. The derivation of the string theory relies on a new interpretation of
Gross and Taylor's ``\Omega^{-1} points.'' We describe how inclusion of the
area, coupling of chiral sectors, and Wilson loop expectation values can be
incorporated in the topological string approach.Comment: 95 pages, 15 Postscript figures, uses harvmac (Please use the "large"
print option.) Extensive revisions of the sections on topological field
theory. Added a compact synopsis of topological field theory. Minor typos
corrected. References adde
Meeting Funders’ Data Policies: Blueprint for a Research Data Management Service Group (RDMSG)
This report summarizes the elements that we expect to be required in data management plans, describes Cornell’s current capabilities and needs in meeting such requirements, and proposes a structure for a virtual organization that builds on the collaboration between the DRSG, CAC, CUL and CISER. The proposed organization also includes Cornell Information Technologies (CIT) and Weill Cornell Medical College Information Technologies and Services (WCMC-ITS) to further develop and provide this support
Drosophila neprilysins control insulin signaling and food intake via cleavage of regulatory peptides
Insulin and IGF signaling are critical to numerous developmental and physiological processes, with perturbations being pathognomonic of various diseases, including diabetes. Although the functional roles of the respective signaling pathways have been extensively studied, the control of insulin production and release is only partially understood. Herein, we show that in Drosophila expression of insulin-like peptides is regulated by neprilysin activity. Concomitant phenotypes of altered neprilysin expression included impaired food intake, reduced body size, and characteristic changes in the metabolite composition. Ectopic expression of a catalytically inactive mutant did not elicit any of the phenotypes, which confirms abnormal peptide hydrolysis as a causative factor. A screen for corresponding substrates of the neprilysin identified distinct peptides that regulate insulin-like peptide expression, feeding behavior, or both. The high functional conservation of neprilysins and their substrates renders the characterized principles applicable to numerous species, including higher eukaryotes and humans. DOI: http://dx.doi.org/10.7554/eLife.19430.00
Tax Loss Offset Restrictions - Last Resort for the Treasury? An Empirical Evaluation of Tax Loss Offset Restrictions Based on Micro Data
Primary treatment of acromegaly with high-dose lanreotide: a case series
<p>Abstract</p> <p>Introduction</p> <p>The first-line treatment for acromegaly is transsphenoidal surgery. In approximately 50% of patients, however, a cure is not possible with surgery and alternatives are needed. Somatostatin analog therapy is the recommended first-line treatment in patients with such cases. Here we provide the first report of a high-dose lanreotide primary therapy in patients with acromegaly.</p> <p>Case presentation</p> <p>Six patients who were not suitable for surgery were given 60 mg of lanreotide (Autogel<sup>®</sup>) every four weeks. All patients were German nationals and Caucasian.</p> <p>When the response of our patients was unsatisfactory, the dose was increased sequentially to 90 mg every four weeks, 120 mg every four weeks, 120 mg every three weeks and 180 mg every three weeks. Treatment duration was 12 to 24 months. In all cases, the lanreotide dose was 120 mg every 4 weeks or higher. In five of our patients, growth hormone (GH) levels were successfully reduced (in three patients GH <2.5 ng/ml was achieved). Insulin-like growth factor 1 levels were normalized in three patients and decreased in two patients. One patient failed to show a biochemical response to lanreotide therapy or pegvisomant therapy.</p> <p>Tumor shrinkage or degeneration was observed in the five responding patients. No drug-related adverse events were noted.</p> <p>Conclusions</p> <p>These results suggest that lanreotide at high doses of 120 mg every four weeks or more is an effective first-line therapy for patients with acromegaly that surgery alone cannot treat.</p
- …